PharmiWeb.com - Global Pharma News & Resources
03-Jul-2019

Antisense and RNAi Therapeutics Market Size to Garner more than US$ 1.9 Billion by 2026

The Global Antisense and RNAi Therapeutics Market Size is expected to reach USD 1.9 Billion by 2026 and growing CAGR around 7.3 % during the forecast period 2018 to 2026.

The Global Antisense and RNAi Therapeutics Market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2018 to 2026. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2018 to 2026.

Request a Sample Copy of this Research Report athttps://www.acumenresearchandconsulting.com/request-sample/1062

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global Antisense and RNAi Therapeutics Market.

Key Takeaways:

  • What is the market size in 2018 and the growth rate of the global Antisense and RNAi Therapeutics Market?
  • What is the market drivers, restrains, opportunities governing the global Antisense and RNAi Therapeutics Market?
  • Which is the largest and the fastest growing segments in the global Antisense and RNAi Therapeutics Market?
  • Who are the key players operating in the market and their market position?
  • What is the pipeline scenario, drug pricing analysis and technological development in the market?

Market Players:

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market. The Antisense and RNAi Therapeutics Market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues.

The major players associated with the Antisense and RNAi Therapeutics Market are Benitec Biopharma, GSK, Alnylam Pharmaceuticals, Sanofi-Genzyme, and Marina Biosciences.

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1062

The Major Market Segments of GlobalAntisense and RNAi Therapeutics Marketare as below:

Market Segmentation

Market By Technology

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

Market By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Other

Market By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Other Delivery Methods

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

North America is a key market, with U.S. mirroring various RNAi therapeutics at present in formative pipelines. Various biotechnology organizations have made significantly high interests in RNAi restorative advancement. Enormous pharmaceutical engineers have gone into cooperation understandings or permitting manages various littler firms trying to gain by the normal revenue development of this market. AstraZeneca's concurrence with Ionis Pharmaceuticals is one of the striking arrangements that mirror the pattern of developing interests in antisense innovation.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Antisense amp; RNAi Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Antisense amp; RNAi Therapeutics Market By Technology
1.2.2.1. Global Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate Comparison By Technology (2015-2026)
1.2.2.2. Global Antisense amp; RNAi Therapeutics Market Revenue Share By Technology in 2017
1.2.2.3. RNA Interference
1.2.2.4. Antisense RNA
1.2.2.5. Others
1.2.3. Antisense amp; RNAi Therapeutics Market By Application
1.2.3.1. Global Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Oncology
1.2.3.3. Cardiovascular
1.2.3.4. Respiratory Disorders
1.2.3.5. Renal Diseases
1.2.3.6. Neurodegenerative Disorders
1.2.3.7. Genetic Disorders
1.2.3.8. Infectious Diseases
1.2.3.9. Others
1.2.4. Antisense amp; RNAi Therapeutics Market By Route of Administration
1.2.4.1. Global Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.4.2. Pulmonary Delivery
1.2.4.3. Intravenous Injections
1.2.4.4. Intradermal Injections
1.2.4.5. Intraperitoneal Injections
1.2.4.6. Topical Delivery
1.2.4.7. Other Delivery Methods
1.2.5. Antisense amp; RNAi Therapeutics Market by Geography
1.2.5.1. Global Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Antisense amp; RNAi Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Antisense amp; RNAi Therapeutics Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Antisense amp; RNAi Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Antisense amp; RNAi Therapeutics Major Manufacturers in 2017

CHAPTER 4. ANTISENSE amp; RNAI THERAPEUTICS MARKET BY TECHNOLOGY

4.1. Global Antisense amp; RNAi Therapeutics Revenue By Technology
4.2. RNA Interference
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Antisense RNA
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTISENSE amp; RNAI THERAPEUTICS MARKET BY APPLICATION

5.1. Global Antisense amp; RNAi Therapeutics Revenue By Application
5.2. Oncology
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Cardiovascular
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Respiratory Disorders
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Renal Diseases
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Neurodegenerative Disorders
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.7. Genetic Disorders
5.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.8. Infectious Diseases
5.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.9. Others
5.9.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.9.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTISENSE amp; RNAI THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION

6.1. Global Antisense amp; RNAi Therapeutics Revenue By Route of Administration
6.2. Pulmonary Delivery
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Intravenous Injections
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Intradermal Injections
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Intraperitoneal Injections
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Topical Delivery
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Other Delivery Methods
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA ANTISENSE amp; RNAI THERAPEUTICS MARKET BY COUNTRY

7.1. North America Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Antisense amp; RNAi Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Antisense amp; RNAi Therapeutics Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE ANTISENSE amp; RNAI THERAPEUTICS MARKET BY COUNTRY

8.1. Europe Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Antisense amp; RNAi Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC ANTISENSE amp; RNAI THERAPEUTICS MARKET BY COUNTRY

9.1. Asia-Pacific Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Antisense amp; RNAi Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA ANTISENSE amp; RNAI THERAPEUTICS MARKET BY COUNTRY

10.1. Latin America Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Antisense amp; RNAi Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST ANTISENSE amp; RNAI THERAPEUTICS MARKET BY COUNTRY

11.1. Middle East Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Antisense amp; RNAi Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA ANTISENSE amp; RNAI THERAPEUTICS MARKET BY COUNTRY

12.1. Africa Antisense amp; RNAi Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Antisense amp; RNAi Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Technology, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Application, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Benitec Biopharma
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. GSK
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Alnylam Pharmaceuticals
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Sanofi-Genzyme
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Marina Biosciences
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Others
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1062

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 03-Jul-2019